E
Sell
3/14/2023Downgrade
Aditxt, Inc. (ADTX) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Aditxt, Inc. (ADTX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Aditxt, Inc. (ADTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/21/2022Upgraded
Aditxt, Inc. (ADTX) was upgraded to D from D- on 11/21/2022 due to a large increase in the growth index, solvency index and total return index. The quick ratio increased from 0.17 to 2.27, debt to equity declined from 1.5 to 0.12, and total revenue increased 50.49% from $214.7 to $323.1.
D
Sell
5/18/2022Upgraded
Aditxt, Inc. (ADTX) was upgraded to D- from E+ on 5/18/2022 due to a large increase in the growth index and valuation index. Total revenue increased 100.29% from $105 to $210.3, earnings per share increased from -$0.7873 to -$0.1359, and operating cash flow increased 40.18% from -$8.69M to -$5.2M.
E
Sell
10/13/2021Downgrade
Aditxt, Inc. (ADTX) was downgraded to E+ from D- on 10/13/2021 due to a decline in the growth index, total return index and valuation index. Operating cash flow declined 23.52% from -$4.05M to -$5.01M.
D
Sell
8/9/2021Downgrade
Aditxt, Inc. (ADTX) was downgraded to D- from D on 8/9/2021 due to a decline in the volatility index and total return index.
D
Sell
7/1/2021Upgraded
ADiTx Therapeutics, Inc. (ADTX) was upgraded to D from D- on 7/1/2021 due to a noticeable increase in the growth index and volatility index.
D
Sell
3/1/2021Upgraded
ADiTx Therapeutics, Inc. (ADTX) was upgraded to D- from E on 3/1/2021 due to a noticeable increase in the volatility index and total return index.
E
Sell
12/1/2020Upgraded
ADiTx Therapeutics, Inc. (ADTX) was upgraded to E from E- on 12/1/2020 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 0.01 to 18.15.
E
Sell
9/23/2020None
Aditxt, Inc. (ADTX) was downgraded to E- from U on 09/23/2020.
